[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100540290":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":29,"collaborators":7,"id":31,"slug":7,"hasResults":32,"nctId":33,"briefTitle":34,"officialTitle":35,"acronym":7,"eligibilityCriteria":36,"healthyVolunteers":32,"sex":37,"minAge":38,"maxAge":7,"enrollmentInfo":39,"targetDuration":7,"studyType":42,"phases":7,"briefSummary":43,"conditions":44,"keywords":7,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":56},{"fullName":5,"class":6},"Boryung Pharmaceutical Co., Ltd","INDUSTRY",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Shin-young Oh","CONTACT","+82-2-708-8000","syoh@boryung.co.kr",[15],{"facility":16,"status":17,"city":18,"state":7,"zip":7,"country":19,"cosmosGeoPoint":20,"geoPoint":25,"contacts":26},"Ewha Womans University Seoul Hospital","RECRUITING","Seoul","South Korea",{"type":21,"coordinates":22},"Point",[23,24],126.9784,37.566,{"lat":24,"lon":23},[27],{"name":28,"role":11,"phone":7,"phoneExt":7,"email":7},"Wook-Bum Pyun, M.D., Ph.D.",{"type":30,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100540290",false,"NCT06314919","A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin\u002FEzetimib","A Multicenter, Prospective, Cohort Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin\u002FEzetimibe Under the Real-World Condition","Inclusion Criteria:\n\n* Those who taking statins or statins and ezetimibe in addition to dietary and exercise therapy for primary hypercholesterolemia or mixed hyperlipidemia\n* Those who are judged to need administration of a fixed-dose combination of pitavastatin\u002Fezetimibe for change of statin's formulation or change of statin's dose, addition of ezetimibe\n\nExclusion Criteria:\n\n* Those who are taking a fixed-dose combination of pitavastatin\u002Fezetimibe at study enrollment\n* Those with hypersensitivity reactions or relevant medical history to pitavastatin or ezetimibe\n* Those who have been administered an investigational product within 12 weeks of the enrollment date or are planning to participate in another clinical trial during this study participation period.","ALL","19 Years",{"count":40,"type":41},8606,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to evaluate the efficacy and safety of fixed-Dose combination of Pitavastatin\u002FEzetimibe under the real-world condition",[45,46],"Primary Hypercholesterolemia","Mixed Dyslipidemia","2025-09-10",{"date":49,"type":50},"2025-09-12","ACTUAL",{"date":52,"type":50},"2024-03-15",{"date":54,"type":41},"2026-06",{"name":5,"class":6},1]